Articles

A panel of experts convened by the US Food and Drug Administration to evaluate neurological devices recommended approval of the NovoTTF-100A system for pre-market use in patients with recurrent supratentorial glioblastoma multiforme (GBM). After reviewing final data from the phase III EF-11 trial, the 12-member panel returned 7 yes votes and 3 no votes, with 2 abstentions, on the question of whether the device’s benefits outweighed its risks.

By Christin Melton

TON - Daily

Lowering the induction dose of cytarabine to 200-mg/m² in patients with acute myeloid leukemia (AML) reduced the rate of treatment-related toxicities but was no less effective than an induction dose >1000 mg/ m² according to a report in the New England Journal of Medicine. Investigators for the phase III multinational study recruited ~860 patients and randomized them 1:1 to an intermediate- or high-dose induction regimen of cytarabine. Read More ›

Tamoxifen Protects Against Breast Cancer For Years After Treatment Ends

TON - Daily

A new study shows that tamoxifen protects high-risk women against breast cancer for as long as a decade after treatment ends. Joyce Noah-Vanhoucke, PhD, Archimedes Inc., San Francisco, California, and colleagues conducted the meta-analysis and found that using tamoxifen to prevent breast cancer in postmenopausal women aged <55 years was cost-effective and saved lives.

By Christin Melton

TON - Daily

A retrospective analysis of Medicare claims for women with advanced epithelial ovarian cancer (EOC) found that only 39% of patients received optimal therapy as outlined by national treatment guidelines. Data were presented at a plenary session at the annual meeting of the Society of Gynecologic Oncology last week. Discussant Michael Carney, MD, University of Hawaii, Honolulu, described the report as "disappointing, shocking, and sad."

By Kimberly Melofchik

TON - Daily

A coalition of healthcare and advocacy groups launched a new Website called “Healthcare and You” last week to help American consumers navigate the ins and outs of the Affordable Care Act. Read More ›

CREBBP Gene Mutations Associated With Resistance and Relapse in Childhood ALL

By Christin Melton

TON - Daily

Children with acute lymphoblastic leukemia (ALL) who have mutations in the CREBBP gene are more likely to relapse according to a team of researchers with St. Jude Children's Research Hospital and the National Cancer Institute. The CREBBP gene produces CREB binding protein, an enzyme involved in cell growth and division. According to the investigators, CREBBP also regulates genes essential to normal blood cell development.

By Christin Melton

TON - Daily

Patients with lung cancer who received daily fish oil supplements experienced greater tumor shrinkage during chemotherapy and longer overall survival (OS) and were less likely to lose weight than patients taking placebo. The study was led by Vera Mazurak, PhD, an expert in nutrition and metabolism with the Department of Agricultural, Food and Nutritional science at the University of Alberta in Canada.

By Christin Melton

TON - Daily

Chemotherapy might contribute to balance problems in postmenopausal women with breast cancer, according to researchers from the Knight Cancer Institute at Oregon Health and Science University. They enrolled 59 breast cancer survivors (average age, 58 years) and compared their incidence of falls with the annual reported rate for historical controls living in a community setting.

By Bonnie Gillis

TON - Daily

ORLANDO, FL— The news was promising regarding several drugs for the treatment of prostate cancer at the recent ASCO Genitourinary Cancers Symposium held February 17-19, 2011 An extension-phase study of degeralix, approved by the FDA in 2008, confirmed the efficacy of this drug versus leuprolide. Other positive studies focused on drugs in various stages of development, including abiraterone, cabozantinib, and MDV3100.

Degarelix (Firmagon, Ferring)

By Christin Melton

TON - Daily

Data published in the Lancet this week support the effectiveness of eribulin mesylate (Halaven)—a microtubule inhibitor—in women with advanced breast cancer that has progressed after several treatments. The FDA approved eribulin in November 2010 for metastatic breast cancer patients treated with at least two chemotherapy regimens (an anthracycline and a taxane). Read More ›

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 348 of 377

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: